| Backhaus P, Cazzamalli S, Oehler S, Buther F, Brosch-Lenz J, Landau F, Breyholz H-J, Claesener M, Migliorini F, Ciamarone A, Georgiev T, Mock J, Ventura D, Barca C, Schiefelbein L, Hermann S, Schafers K, Gierse F, Bernemann C, Schlack K, Bogemann M, Puca E, Schindler P, Neri D, Rahbar K, Schrader AJ, Seifert KE, Schafers M. Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [(68)Ga]Ga-OncoACP3-DOTA. Eur Urol 2026;89: 305-310. Abstract
|
| Backhaus P, Cazzamalli S, Oehler S, Buther F, Brosch-Lenz J, Landau F, Breyholz H-J, Claesener M, Migliorini F, Ciamarone A, Georgiev T, Mock J, Ventura D, Barca C, Schiefelbein L, Hermann S, Schafers K, Gierse F, Bernemann C, Schlack K, Bogemann M, Puca E, Schindler P, Neri D, Rahbar K, Schrader AJ, Seifert KE, Schafers M. Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [(68)Ga]Ga-OncoACP3-DOTA. Eur Urol 2026;89: 305-310. Abstract
|
| Brosch-Lenz J, Buther F, Oehler S, Ciamarone A, Georgiev T, Schindler P, Landau F, Breyholz H-J, Ventura D, Rust M, Schlack K, Bogemann M, Puca E, Mock J, Cazzamalli S, Neri D, Rahbar K, Schrader AJ, Schafers M, Seifert KE, Backhaus P. Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [(68)Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer. J Nucl Med 2026;67: 1079-1085. Abstract
|
| Brosch-Lenz J, Buther F, Oehler S, Ciamarone A, Georgiev T, Schindler P, Landau F, Breyholz H-J, Ventura D, Rust M, Schlack K, Bogemann M, Puca E, Mock J, Cazzamalli S, Neri D, Rahbar K, Schrader AJ, Schafers M, Seifert KE, Backhaus P. Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [(68)Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer. J Nucl Med 2026;67: 1079-1085. Abstract
|
| Ventura D, Schafers M, Bobe S, Buther F, Brandt J, Stegger L, Bruggemann P, Roll W, Rahbar K, Schindler P, Backhaus P. FAP-targeted [(68)Ga]BED003-PET in different solid malignancies. Eur J Nucl Med Mol Imaging 2026;53: 4977-4987. Abstract
|
| Ventura D, Schafers M, Bobe S, Buther F, Brandt J, Stegger L, Bruggemann P, Roll W, Rahbar K, Schindler P, Backhaus P. FAP-targeted [(68)Ga]BED003-PET in different solid malignancies. Eur J Nucl Med Mol Imaging 2026;53: 4977-4987. Abstract
|
| Ventura D, Schafers M, Bobe S, Buther F, Brandt J, Stegger L, Bruggemann P, Roll W, Rahbar K, Schindler P, Backhaus P. FAP-targeted [(68)Ga]BED003-PET in different solid malignancies. Eur J Nucl Med Mol Imaging 2026;53: 4977-4987. Abstract
|
| Backhaus P, Cazzamalli S, Oehler S, Buther F, Brosch-Lenz J, Landau F, Breyholz H-J, Claesener M, Migliorini F, Ciamarone A, Georgiev T, Mock J, Ventura D, Barca C, Schiefelbein L, Hermann S, Schafers K, Gierse F, Bernemann C, Schlack K, Bogemann M, Puca E, Schindler P, Neri D, Rahbar K, Schrader AJ, Seifert KE, Schafers M. Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [(68)Ga]Ga-OncoACP3-DOTA. Eur Urol 2025Abstract
|
| Backhaus P, Seitzer K, Cazzamalli S, Oehler S, Migliorini F, Ciamarone A, Georgiev T, Mock J, Bögemann M, Breyholz HJ, Landau F, Büther F, Puca E, Neri D, Rahbar K, Schrader A, Schäfers M. A new theranostic target in prostate cancer: First results from prostatic acid phosphatase (ACP3) imaging with [68Ga]Ga-OncoACP3-DOTA PET in prostate cancer patients and comparison to [18F]F-PSMA-1007 2025;66
|
| Seifert KE, Schlack K, Cazzamalli S, Oehler S, boegemann M, Migliorini F, Ciamarone A, Georgiev T, Mock JC, Breyholz H-J, Ventura D, Landau F, Buether F, Puca E, Neri D, Rahbar K, Schrader AJ, Schäfers M, Backhaus P. Imaging and treatment of the prostatic acid phosphatase with [68Ga]Ga-OncoACP3-DOTA and [177Lu]Lu-OncoACP3-DOTA in prostate cancer patients. Annals of Oncology 2025;36: S1220-S1221. Abstract
|
| Cufe J, Gierse F, Schafers KP, Hermann S, Schafers MA, Backhaus P, Buther F. Dispersion-corrected extracorporeal arterial input functions in PET studies of mice: a comparison to intracorporeal microprobe measurements. EJNMMI Res 2023;13: 86. Abstract
|
| Cufe J, Gierse F, Schäfers KP, Hermann S, Schäfers MA, Backhaus P, Büther F. Dispersion-corrected extracorporeal arterial input functions in PET studies of mice: a comparison to intracorporeal microprobe measurements. EJNMMI Res 2023;13: 86. Abstract
|
| Galbiati A, Dorten P, Gilardoni E, Gierse F, Bocci M, Zana A, Mock J, Claesener M, Cufe J, Büther F, Schäfers K, Hermann S, Schäfers M, Neri D, Cazzamalli S, Backhaus P. Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics. J Nucl Med 2023Abstract
|
| Backhaus P, Burg MC, Asmus I, Pixberg M, Büther F, Breyholz H-J, Yeh R, Weigel SB, Stichling P, Heindel W, Bobe S, Barth P, Tio J, Schäfers M. Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer. J Nucl Med 2022Abstract
|
| Backhaus P, Burg MC, Roll W, Büther F, Breyholz H-J, Weigel S, Heindel W, Pixberg M, Barth P, Tio J, Schäfers M. Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer. Radiology 2022;302: 39-47. Abstract
|
| Backhaus P, Gierse F, Burg MC, Büther F, Asmus I, Dorten P, Cufe J, Roll W, Neri D, Cazzamalli S, Millul J, Mock J, Galbiati A, Zana A, Schäfers KP, Hermann S, Weckesser M, Tio J, Wagner S, Breyholz H-J, Schäfers M. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [(68)Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging 2022;49: 1822-1832. Abstract
|
| Noto B, Roll W, Zinken L, Rischen R, Kerschke L, Evers G, Heindel W, Schäfers M, Büther F. Respiratory motion correction in F-18-FDG PET/CT impacts lymph node assessment in lung cancer patients. EJNMMI Res 2022;12: 61. Abstract
|
| Vehof V, Büther F, Florian A, Drakos S, Chamling B, Kies P, Stegger L, Yilmaz A. Hybrid CMR- and FDG-PET-Imaging Gives New Insights Into the Relationship of Myocardial Metabolic Activity and Fibrosis in Patients With Becker Muscular Dystrophy. Front Cardiovasc Med 2022;9: 793972. Abstract
|
| Backhaus P, Büther F, Wachsmuth L, Frohwein L, Buchholz R, Karst U, Schäfers K, Hermann S, Schäfers M, Faber C. Toward precise arterial input functions derived from DCE-MRI through a novel extracorporeal circulation approach in mice. Magn Reson Med 2020;84: 1404-1415. Abstract
|
| Büther F, Jones J, Seifert R, Stegger L, Schleyer P, Schäfers M. Clinical Evaluation of a Data-Driven Respiratory Gating Algorithm for Whole-Body PET with Continuous Bed Motion. J Nucl Med 2020;61: 1520-1527. Abstract
|
| Pösse S, Büther F, Mannweiler D, Hong I, Jones J, Schäfers M, Schäfers KP. Comparison of two elastic motion correction approaches for whole-body PET/CT: motion deblurring vs gate-to-gate motion correction. EJNMMI Phys 2020;7Abstract
|
| Büther F, Dawood M, Stegger L, Wübbeling F, Schäfers M, Schober O, Schäfers KP. List mode-driven cardiac and respiratory gating in PET. J Nucl Med 2009;50: 674-681. Abstract
|
| Dawood M, Büther F, Schober O, Schäfers M, Schäfers KP. Wieviele respiratorische Gates? Einfluss der Anzahl an Gates auf atemgetriggerte PET Aufnahmen. Nuklearmedizin 2009;48: A23.
|
| Dawood M, Büther F, Stegger L, Jiang X, Schober O, Schäfers M, Schäfers KP. Optimal number of respiratory gates in positron emission tomography: a cardiac patient study. Med Phys 2009;36: 1775-1784. Abstract
|
| Ernst I, Büther F, Dawood M, Kraxner P, Moustakis C, Bolling T, Schober O, Schäfers K, Willich N. PET/CT for movement detection in high precision radiotherapy. Strahlenther Onkol 2009;185: 35-36.
|